Valeant Pharma (NYSE: VRX) released the slides for its upcoming 8AM conference to address concerns about its relationship an use of specialty pharmacies.

The slides don't appear to address today's new revelation from the Wall Street Journal that employees of Philidor also worked at Valeant and used alternative names in e-mails.

The PDF could not be displayed inside the page, click here to open.

Conference Calls Momentum Movers Short Sales Trader Talk

Valeant Pharmaceuticals' (VRX) Buy Rating Affirmed at TD SecuritiesOctober 26, 2015 3:33 PM Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Valeant (VRX) CC Seen as Step Forward at BMO Capital But More Needed to Rebuild Investor ConfidenceOctober 26, 2015 10:35 AM UPDATE: Valeant Pharma (VRX) Sees Dramatic Red-to-Green Reversal Then Collapses AgainOctober 26, 2015 9:40 AM Mizuho Provides Quick Thoughts on Valeant (VRX) Slides/CallOctober 26, 2015 9:14 AM Valeant Pharma (VRX) says ad hoc committee will review issues brought up in today's WSJOctober 26, 2015 8:43 AM Valeant Pharma (VRX) Regains Some Early Losses as Conference Call StartsOctober 26, 2015 8:09 AM WSJ Highlights More 'Smoke' at Valeant Pharma (VRX) Ahead of Conference CallOctober 26, 2015 6:39 AM Valeant Pharma (VRX) Says Philidor Accounting is AppropriateOctober 26, 2015 6:16 AM Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review PhilidorOctober 26, 2015 6:15 AM Valeant Pharma (VRX) Adds ValueAct's Morfit as DirectorOctober 26, 2015 6:13 AM